Radiolabeled mAbs as Molecular Imaging and/or Therapy Agents Targeting PSMA

被引：12

作者：

Psimadas, Dimitrios ^{[1
]}

Valotassiou, Varvara ^{[1
]}

Alexiou, Sotiria ^{[1
]}

Tsougos, Ioannis ^{[1
]}

Georgoulias, Panagiotis ^{[1
]}

机构：

[1] Univ Thessaly, Sch Med, Univ Hosp Larissa, Dept Nucl Med, Larisa, Greece

来源：

CANCER INVESTIGATION | 2018年 / 36卷 / 02期

关键词：

Antibodies; radiolabeling; PSMA; prostate cancer; LU-177-PSMA-617 RADIOLIGAND THERAPY; METASTATIC PROSTATE-CANCER; MEMBRANE ANTIGEN PSMA; MONOCLONAL-ANTIBODY J591; IN-VIVO; PRECLINICAL EVALUATION; EXTRACELLULAR DOMAIN; RADIATION-DOSIMETRY; INHIBITORS; TUMORS;

D O I：

10.1080/07357907.2018.1430816

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Molecular imaging and therapy is a rapidly evolving field in research and clinical medicine. The use of the exciting and attractive properties of radioisotopes for imaging and therapy has made Nuclear Medicine very significant when it comes to molecular imaging/therapy. Monoclonal Antibodies (mAbs) on the other hand are very important targeting biomolecules with high affinity that can "carry" the radioisotope of choice. Herein we make a brief overview of the radiolabeled mAbs that target prostate specific membrane antigen (PSMA) and their use in the management of patients with prostate cancer (PCa).

引用

页码：118 / 128

页数：11

共 50 条

[41] PSMA-targeted contrast agents for intraoperative imaging of prostate cancer
Bao, Kai
Lee, Jeong Heon
Kang, Homan
Park, G. Kate
El Fakhri, Georges
Choi, Hak Soo
CHEMICAL COMMUNICATIONS, 2017, 53 (10) : 1611 - 1614
[42] Glu-Urea-Lys Scaffold Functionalized Superparamagnetic Iron Oxide Nanoparticles Targeting PSMA for In Vivo Molecular MRI of Prostate Cancer
Zhou, Wei
Huang, Jiandong
Xiao, Qingwei
Hu, Shunmin
Li, Shijia
Zheng, Jie
Du, Zhiyun
Peng, Jiangling
Chen, Huixiong
PHARMACEUTICS, 2022, 14 (10)
[43] Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer
Eder, Matthias
Schaefer, Martin
Bauder-Wuest, Ulrike
Haberkorn, Uwe
Eisenhut, Michael
Kopka, Klaus
PROSTATE, 2014, 74 (06): : 659 - 668
[44] Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging: The PSMA PET Progression Criteria
Fanti, Stefano
Hadaschik, Boris
Herrmann, Ken
JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (05) : 678 - 682
[45] Molecular Imaging of Cancer with Radiolabeled Peptides and PET
Vavere, Amy L.
Rossin, Raffaella
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2012, 12 (05) : 462 - 475
[46] Application of radiolabeled peptides in tumor imaging and therapy
Mohtavinejad, Naser
Ardestani, Mehdi Shafiee
Khalaj, Ali
Pormohammad, Ali
Najafi, Reza
Bitarafan-Rajabi, Ahmad
Hajiramezanali, Maliheh
Amanlou, Massoud
LIFE SCIENCES, 2020, 258
[47] Radiolabeled Gold Nanoparticles for Imaging and Therapy of Cancer
Silva, Francisco
Cabral Campello, Maria Paula
Paulo, Antonio
MATERIALS, 2021, 14 (01) : 1 - 32
[48] Molecular imaging and therapy targeting copper metabolism in hepatocellular carcinoma
Wachsmann, Jason
Peng, Fangyu
WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (01) : 221 - 231
[49] Current State of Radiolabeled Heterobivalent Peptidic Ligands in Tumor Imaging and Therapy
Judmann, Benedikt
Braun, Diana
Waengler, Bjorn
Schirrmacher, Ralf
Fricker, Gert
Waengler, Carmen
PHARMACEUTICALS, 2020, 13 (08) : 1 - 31
[50] Targeted alpha-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine
Chakravarty, Rubel
Siamof, Cerise M.
Dash, Ashutosh
Cai, Weibo
AMERICAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 8 (04): : 247 - 267

← 1 2 3 4 5 →